# Neoadjuvant Study of DV in Combination Toripalimab or Sequence Chemotherapy in HR-negative, HER2 Low-expressing Breast Cancer

Source: https://onco.cc/trials/nct06227117/  
OnCo record `nct06227117` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Disitamab vedotin, Toripalimab, Carboplatin and Epirubicin in HER2-positive breast cancer, run by RemeGen Co., Ltd., now recruiting.

## Summary

Neoadjuvant Study of DV in Combination Toripalimab or Sequence Chemotherapy in HR-negative, HER2 Low-expressing Breast Cancer is a phase 2 interventional study registered as NCT06227117 by RemeGen Co., Ltd., with 120 participants planned, started 2023-07-27 and due to reach its primary completion in 2025-12. Interventions recorded: Disitamab Vedotin Injection （18 weeks）, Toripalimab （18weeks）, Carboplatin, Disitamab Vedotin Injection （12 weeks）, Sequential Epirubicin and Sequential CTX.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06227117
- Phase: 2
- Setting: A Randomized, Multicenter, Open-Label Phase II Neoadjuvant Study to Evaluate the Safety and Efficacy of Disitamab Vedotin in Combination Toripalimab or Sequence Chemotherapy in Participants With HR-negative, HER2 Low-expressing Breast Cancer
- Sponsor: RemeGen Co., Ltd.
- Enrolled: 120

## Sources

- ClinicalTrials.gov NCT06227117: https://clinicaltrials.gov/study/NCT06227117

## Connected records

- cancers: [HER2-positive breast cancer](https://onco.cc/cancers/breast-her2-positive/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Disitamab vedotin](https://onco.cc/drugs/disitamab-vedotin/), [Epirubicin](https://onco.cc/drugs/epirubicin/), [Toripalimab](https://onco.cc/drugs/toripalimab/)
- companies: [RemeGen](https://onco.cc/companies/remegen/)

---
JSON: https://onco.cc/api/v1/entities/nct06227117.json